B1486 is a highly potent VprBP inhibitor capable of blocking osteoclast differentiation and bone resorption.

Sungmin Kim, Yonghwan Shin, Nikhil B Ghate, Woojin An

Abstract read

In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sungmin KimDepartment of Cancer Biology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.

Yonghwan ShinDepartment of Cancer Biology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.

Nikhil B GhateDepartment of Cancer Biology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.

Woojin AnDepartment of Cancer Biology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA. Electronic address: woojinan@usc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone is a dynamic tissue that is continuously remodeled by tightly coordinated actions of bone-resorbing osteoclasts and bone-forming osteoblasts. Uncontrolled osteoclastogenesis has a severe impact on skeletal health and thus represents an important therapeutic target in osteolytic diseases. VprBP is a recently identified kinase and plays an important role in stimulating osteoclast differentiation and bone resorption through histone H2AT120 phosphorylation (H2AT120p). We previously developed B32B3 as the first VprBP inhibitor, but its high IC

Indexed as

histoneinhibitorosteoclastphosphorylationprotein kinase

Identifiers

PMID42710660

DOI10.1016/j.jbc.2026.113524

PMCPMC13671033

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.